ACHN Achillion Pharmaceuticals, Inc.

[greencat]

ACHN had a lower low and doule top. ACHN has broken through the double top and I now think it may challenge old highs. Breaking through a double top is very bullish.

ACHN Chart


Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511
United States - Map
Phone: 203-624-7000
Fax: 203-624-7003
Web Site: Achillion Pharmaceuticals, Inc.

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: N/A


BUSINESS SUMMARY
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidate pipeline includes ACH-1625, a protease inhibitor, which is in phase 1/b clinical trials for the treatment of chronic hepatitis C infections; ACH-1095, a NS4A antagonist that is in late-stage preclinical studies for the treatment of chronic hepatitis C infections; and ACH-2684, a protease inhibitor, which is in late stage preclinical testing. The company’s other product candidates comprise ACH-702, which is in preclinical stage for the treatment of serious bacterial infections; and Elvucitabine that is in phase II clinical trials for the treatment of HIV infection. The company has a collaboration arrangement with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C, which inhibit viral replication through a mechanism of action. Achillion Pharmaceuticals, Inc. was founded in 1998 and is based in New Haven, Connecticut.